Ophthalmology AdvisorYuvezzi Approved as Once-Daily Combination Therapy for Presbyopia

The FDA has approved Yuvezzi (carbachol/brimonidine 2.75%/0.1%), the first fixed-dose combination presbyopia drop, with commercial availability expected Q2 2026. Phase 3 trials showed up to 51% of patients gaining 3 lines of near vision at peak effect versus 3.7% on vehicle.

⚖️ Professional Impact

• Combination therapy outperformed individual components: at 2 hours, 51.1% achieved the primary endpoint vs 39.8% on carbachol and 26.7% on brimonidine alone
• Effect duration is meaningful but limited: statistically significant near vision benefit extends to 6 hours; effect diminishes sharply by hour 8
• Retinal detachment risk and iritis are listed warnings; myopic patients and those with retinal pathology require careful screening before prescribing
• Once-daily dosing and single-use vials dosed bilaterally simplify workflow compared to current presbyopia drop options

🎯 Action Items

• Screen patients with myopia or retinal history before initiating Yuvezzi
• Counsel patients that peak effect occurs at 1 to 2 hours; time dosing to daily near-vision demands
• Compare Yuvezzi positioning against pilocarpine 1.25% (Vuity) in your presbyopia counseling protocol
• Track Q2 2026 commercial launch for formulary and optical dispensary planning

More on Presbyopia